Private company

Paratek Pharmaceuticals, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.”77 It is headquartered in Boston, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address75 Park Plaza, 4Th Floor, Boston, Ma 021162
  • Filer categoryAccelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-28.8%Operating margin3
-39.7%Net margin3
23.1%Revenue growth, 20223

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue12¢$23.1M
  • Selling, general and admin78¢$145.6M
  • Interest10¢$18.1M
  • Income tax0¢$57.0K

Out of $160.3M in revenue.3 The company lost money this year.

Financial statements

Revenue456783$160.3M in 2022+552548% since 2016
0$50.0M$100.0M$150.0M$200.0M2016: $29.0K$29.0K20162017: $12.6M$12.6M2017+43403%2018: $17.1M$17.1M2018+36%2019: $16.5M$16.5M2019−3%2020: $46.9M$46.9M2020+184%2021: $130.2M$130.2M2021+177%2022: $160.3M$160.3M2022+23%
Operating income456783-$46.2M in 2022−58% since 2016
-$150.0M-$100.0M-$50.0M02016: -$109.5M-$109.5M20162017: -$84.6M-$84.6M2017−23%2018: -$104.1M-$104.1M2018+23%2019: -$115.6M-$115.6M2019+11%2020: -$75.5M-$75.5M2020−35%2021: -$41.1M-$41.1M2021−46%2022: -$46.2M-$46.2M2022+12%
Net income456783-$63.6M in 2022−43% since 2016
-$150.0M-$100.0M-$50.0M02016: -$111.6M-$111.6M20162017: -$89.1M-$89.1M2017−20%2018: -$112.4M-$112.4M2018+26%2019: -$128.8M-$128.8M2019+15%2020: -$96.5M-$96.5M2020−25%2021: -$59.1M-$59.1M2021−39%2022: -$63.6M-$63.6M2022+8%
Fiscal year2016201720182019202020212022
Revenue$29.0K4$12.6M5$17.1M6$16.5M7$46.9M8$130.2M3$160.3M3
Cost of revenue$3.5M7$8.7M8$21.5M3$23.1M3
Selling, general and admin$63.7M6$89.1M7$89.9M8$119.4M3$145.6M3
Operating expenses$171.3M3$206.5M3
Operating income-$109.5M4-$84.6M5-$104.1M6-$115.6M7-$75.5M8-$41.1M3-$46.2M3
Interest$3.2M4$5.1M5$11.0M6$16.4M7$20.2M8$17.4M3$18.1M3
Income before tax-$58.5M3-$63.5M3
Income tax$011$753.0K5$502.0K6$301.0K7$600.0K3$57.0K3
Net income-$111.6M4-$89.1M5-$112.4M6-$128.8M7-$96.5M8-$59.1M3-$63.6M3
Earnings per share-$1.223-$1.173
Earnings per share (diluted)-$1.223-$1.173
Shares (weighted, basic)48.4M shares354.4M shares3
Shares (weighted, diluted)48.4M shares354.4M shares3

Compare Paratek Pharmaceuticals, Inc. with another company

Corporate structure

Paratek Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Paratek Pharmaceuticals, Inc.

  • CONTINENTAL GENERAL INSURANCE CO Filed SC 13G on Paratek Pharmaceuticals, Inc., latest Sep 5, 2023
  • NexPoint Real Estate Opportunities, LLC Filed SC 13D/A on Paratek Pharmaceuticals, Inc., latest Jun 27, 2023 (3 filings since Jan 20, 2023)
  • Orin Hirschman Filed SC 13G/A on Paratek Pharmaceuticals, Inc., latest Mar 20, 2023 (4 filings since Mar 9, 2022)
  • Laurence W. Lytton Filed SC 13G/A on Paratek Pharmaceuticals, Inc., latest Feb 13, 2023 (2 filings since May 18, 2022)
  • James D. Dondero Filed SC 13G on Paratek Pharmaceuticals, Inc., latest Mar 11, 2022
  • HIGHBRIDGE CAPITAL MANAGEMENT LLC Filed SC 13G/A on Paratek Pharmaceuticals, Inc., latest Feb 11, 2022
  • Paratek Pharmaceuticals, Inc. Boston, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Paratek Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.1M3 Dec 31, 2022$3.1M3 Dec 31, 2021+1.1%
Accumulated depreciation$2.5M3 Dec 31, 2022$2.3M3 Dec 31, 2021+9.4%
Property and equipment, net$616.0K3 Dec 31, 2022$794.0K3 Dec 31, 2021−22.4%
Operating-lease assets (leased space)$1.8M3 Dec 31, 2022$1.8M3 Dec 31, 2021+1.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$34.2M3 Dec 31, 2022$80.4M3 Dec 31, 2021−57.4%
Marketable securities, current$03 Dec 31, 2022$15.1M3 Dec 31, 2021−100.0%
Debt securities available for sale$03 Dec 31, 2022$15.1M3 Dec 31, 2021−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$829.0K3 Dec 31, 2022$829.0K3 Dec 31, 20210%

Inventory

ItemLatestA year beforeChange
Inventory, total$16.6M3 Dec 31, 2022$11.0M3 Dec 31, 2021+50.3%
Raw materials$903.0K3 Dec 31, 2022$1.1M3 Dec 31, 2021−16.5%
Work in process$30.0M3 Dec 31, 2022$24.7M3 Dec 31, 2021+21.6%
Finished goods$17.0M3 Dec 31, 2022$13.0M3 Dec 31, 2021+30.2%

Leadership

Who has led Paratek Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bradford S. Goodwin2006
  2. Glenn A. Oclassen2009–2014
  3. Michael Bigham2014–2019
  4. Evan Loh2019–2023

Chair

  1. Michael Bigham2014–2023

President

  1. John G. Curd2006–2007
  2. Glenn A. Oclassen2009–2014
  3. Evan Loh2015–2019
  4. Adam Woodrow2019–2023

Chief financial officer

  1. Edward C. Albini2006–2008
  2. Thomas P. Soloway2009–2012
  3. Leone D. Patterson2012–2014
  4. Douglas W. Pagan2014–2019

Chief operating officer

  1. Thomas P. Soloway2013
  2. Evan Loh2017–2019
2010201520202025
Board members and other officers (41)

Former names

  • Transcept Pharmaceuticals IncOct 31, 2008 to Oct 30, 20142
  • NOVACEA INCJul 23, 2002 to Jan 20, 20092

Timeline

  1. Sep 21, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale63
  2. Sep 18, 20238-K Shareholder vote; Other events64
  3. Sep 11, 20238-K Other events65
  4. Jul 11, 20238-K Shareholder vote66
  5. Jun 7, 20238-K Entered a material agreement; Executive or director change; Other events67
  6. Mar 14, 20238-K Bylaws or fiscal year changed68
  7. Jun 9, 20228-K Shareholder vote69
  8. Oct 7, 2019New chief executive Evan Loh becomes CEO12
  9. Nov 3, 2014New chief executive Michael Bigham becomes CEO13
  10. Feb 3, 2009New chief executive Glenn A. Oclassen becomes CEO14
  11. May 9, 2006New chief executive Bradford S. Goodwin becomes CEO15

Filings

172 filings to the SEC since October 2021: 3 annual reports, 6 quarterly reports, 7 major events, 71 insider forms, 14 large holders, 71 other. The latest 20:

  1. Oct 2, 202315-12G EDGAR
  2. Sep 25, 2023EFFECT EDGAR
  3. Sep 21, 202325-NSE EDGAR
  4. Sep 21, 2023SC 13E3/A EDGAR
  5. Sep 21, 2023POS AM EDGAR
  6. Sep 21, 2023S-8 POS EDGAR
  7. Sep 21, 2023S-8 POS EDGAR
  8. Sep 21, 2023S-8 POS EDGAR
  9. Sep 21, 2023S-8 POS EDGAR
  10. Sep 21, 2023S-8 POS EDGAR
  11. Sep 21, 2023S-8 POS EDGAR
  12. Sep 21, 2023S-8 POS EDGAR
  13. Sep 21, 2023S-8 POS EDGAR
  14. Sep 21, 2023S-8 POS EDGAR
  15. Sep 21, 2023S-8 POS EDGAR
  16. Sep 21, 2023S-8 POS EDGAR
  17. Sep 21, 2023S-8 POS EDGAR
  18. Sep 21, 2023S-8 POS EDGAR
  19. Sep 21, 2023S-8 POS EDGAR
  20. Sep 21, 2023S-8 POS EDGAR

The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 5 buys and 45 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 9, 2023Brenner Randall B.Chief Development & RegulatorySale27,603$2.20$60.7KForm 4
Aug 9, 2023BIGHAM MICHAELExec. Chairman of the BoardSale31,250$2.20$68.8KForm 4
Aug 9, 2023Haskel William M.CLO, General Counsel & Sec.Sale34,526$2.20$76.0KForm 4
Aug 9, 2023Loh EvanCEOSale48,967$2.20$107.7KForm 4
Mar 23, 2023DONDERO JAMES D10% ownerBuy100,000$1.73$173.0KForm 4
Mar 22, 2023DONDERO JAMES D10% ownerBuy106,000$1.77$187.6KForm 4
Mar 21, 2023DONDERO JAMES D10% ownerBuy242,500$1.74$421.9KForm 4
Mar 20, 2023DONDERO JAMES D10% ownerBuy105,137$1.40$147.2KForm 4
Mar 17, 2023DONDERO JAMES D10% ownerBuy234,863$1.50$352.3KForm 4
Feb 21, 2023Stein JeffreyDirectorSale7,000$1.90$13.3KForm 4
Feb 21, 2023Franson Timothy RDirectorSale7,000$1.88$13.2KForm 4
Dec 21, 2022Woodrow AdamPresident & Chief CommercialSale6,750$1.99$13.4KForm 4
Dec 21, 2022Loh EvanCEOSale23,489$1.99$46.7KForm 4
Dec 21, 2022Haskel William M.CLO, General Counsel & Sec.Sale7,007$1.99$13.9KForm 4
Dec 21, 2022Brenner Randall B.Chief Development & RegulatorySale4,539$1.99$9.0KForm 4
Dec 21, 2022BIGHAM MICHAELExec. Chairman of the BoardSale15,750$1.99$31.3KForm 4
Dec 13, 2022Woodrow AdamPresident & Chief CommercialSale6,253$1.96$12.3KForm 4
Dec 13, 2022Loh EvanCEOSale61,919$1.96$121.4KForm 4
Dec 13, 2022Haskel William M.CLO, General Counsel & Sec.Sale23,584$1.96$46.2KForm 4
Dec 13, 2022Brenner Randall B.Chief Development & RegulatorySale18,177$1.96$35.6KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Paratek Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARParatek Pharmaceuticals, Inc.1
  • CIK0001178711
  • Employer ID (EIN)33-09602231
  • Filer statusAccelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address75 Park Plaza, 4Th Floor, Boston, MA 021161
  • Phone(617) 807-66001
  • Shares outstanding57,322,358 as of Jul 31, 202310
  • Public float$101.3M as of Jun 30, 202276
  • On EDGAR sinceJul 23, 20021
  • Filings1,336 in all: 4 (527), 8-K (255), 3 (77), 10-Q (53), SC 13G/A (51), DEFA14A (39), SC 13G (37), S-8 (23)1
    All 54 form types

    S-8 POS (23), 425 (21), 4/A (20), SC 13D/A (20), UPLOAD (18), 10-K (17), DEF 14A (17), CORRESP (14), CT ORDER (14), 424B5 (12), EFFECT (12), S-3 (10), SC 13D (10), 8-K/A (7), S-4/A (5), SC 13E3/A (5), REGDEX (4), S-1/A (4), 10-K/A (3), 10-Q/A (3), 3/A (3), 424B3 (3), PRE 14A (2), PREC14A (2), PRER14A (2), S-3/A (2), S-4 (2), 15-12G (1), 25 (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), DEFC14A (1), DEFM14A (1), DEFR14A (1), FWP (1), NT 10-K (1), POS AM (1), PREM14A (1), REGDEX/A (1), RW (1), S-1 (1), S-4MEF (1), SC 13E3 (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2023
    Quarterly report (10-Q) Aug 3, 2023
    Proxy statement (DEF 14A) May 26, 2023
    Latest 8-K (8-K) Sep 21, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
    SEC EDGAROther events
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77